AbCellera Biologics Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
AbCellera Biologics Inc. (ABCL) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$54.11 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-24
- AbCellera Biologics Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$54.11M.
- AbCellera Biologics Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$46.99M, a 172.79% decline from fiscal 2022.
- AbCellera Biologics Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2022 was $64.56M, a 9.10% increase from fiscal 2021.
- AbCellera Biologics Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2021 was $59.17M, a 38.85% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2024-12-31 | -$54.11M 10-K · filed 2026-02-24 |
| 2023-12-31 | -$46.99M 10-K · filed 2026-02-24 |
| 2022-12-31 | $64.56M 10-K · filed 2025-02-27 |
| 2021-12-31 | $59.17M 10-K · filed 2024-02-20 |
| 2020-12-31 | $42.62M 10-K · filed 2023-02-21 |
| 2019-12-31 | -$597.00K 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |